4-(7-butyl-1,5-dihydropyrrolo[2,3-b]pyrazin-6-ylidene)cyclohexa-2,5-dien-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(7-butyl-1,5-dihydropyrrolo[2,3-b]pyrazin-6-ylidene)cyclohexa-2,5-dien-1-one
• 化学式: C₁₆H₁₇N₃O
• 分子量: 267.33
• InChiKey: AYIIQABSVDIZSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Method for the prognosis and treatment of cancer metastasis
  申请人：Fundació Institut de Recerca Biomèdica (IRB Barcelona)

  公开号：US10866241B2

  公开（公告）日：2020-12-15

  The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.

  本发明涉及一种三阴性（包括基底样）乳腺癌或ER+乳腺癌（包括管腔A型和B型）骨转移的预后判断方法，该方法包括确定原发肿瘤样本中c-MAF基因是否扩增。同样，本发明还涉及一种确定相对于其他器官转移的骨转移倾向的方法，其中包括确定 c-MAF 基因的表达水平、扩增或易位。本发明还涉及一种预测乳腺癌患者早期骨转移的方法。本发明还涉及一种用于治疗三阴性（包括基底样）乳腺癌转移或ER+乳腺癌（包括管腔A和B）转移的治疗剂c-MAF抑制剂。本发明涉及用于预测骨转移和预测骨转移患者临床结果的试剂盒。最后，本发明涉及一种对乳腺癌患者进行分型和将乳腺癌患者归入队列的方法。